Cargando…

Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1

BACKGROUND: Most eye disorders are not fatal but may deteriorate the quality of life of a patient. The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). However, preventive methods or treatment me...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuriki, Reiko, Hata, Tsuyoshi, Nakayama, Kinuyo, Ito, Yuichi, Misawa, Kazunari, Ito, Seiji, Tatematsu, Michiko, Kaneda, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803866/
https://www.ncbi.nlm.nih.gov/pubmed/29445512
http://dx.doi.org/10.1186/s40780-018-0100-8
_version_ 1783298716784918528
author Kuriki, Reiko
Hata, Tsuyoshi
Nakayama, Kinuyo
Ito, Yuichi
Misawa, Kazunari
Ito, Seiji
Tatematsu, Michiko
Kaneda, Norio
author_facet Kuriki, Reiko
Hata, Tsuyoshi
Nakayama, Kinuyo
Ito, Yuichi
Misawa, Kazunari
Ito, Seiji
Tatematsu, Michiko
Kaneda, Norio
author_sort Kuriki, Reiko
collection PubMed
description BACKGROUND: Most eye disorders are not fatal but may deteriorate the quality of life of a patient. The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). However, preventive methods or treatment methods for the eye disorder have not yet been established. This study aimed to determine changes in tear volume and subjective ocular symptoms during the treatment period in patients receiving S-1 monotherapy for early detection of adverse effects in the eye and establishment of its treatment methods. METHODS: This study included eleven patients receiving S-1 monotherapy as a postoperative adjuvant chemotherapy for gastric cancer. Six subjective ocular symptoms including watering eyes were evaluated and changes in tear volume measured by the Schirmer’s test in patients receiving S-1 during the treatment period. In the present study, the patients were divided into “no watering eyes” (patients not experienced watering eyes) group and “watering eyes” (patients experienced watering eyes even once) group. RESULTS: Six out of eleven patients developed watering eyes after receiving S-1 monotherapy. Among these, the earliest onset occurred on the 2nd week after oral administration. Watering eyes and eye discharge were highly related in patients having a trouble in daily life due to the decreased QOL. Changes in tear volume in the “watering eyes” group significantly increased compared to the “no watering eyes” group during the treatment period, especially when the patients had no subjective symptom of the increased tear volume. CONCLUSIONS: It is essential to prevent eye disorders including watering eyes as an adverse effect of S-1 administration. The present study recommends that the tear volume should be periodically measured using Schirmer’s test, and the patient should be interviewed regarding the subjective ocular symptoms for the early detection of watering eyes caused by S-1 administration. If the tear volume can not be measured periodically, medical staffs should pay attention to the patient with eye discharge.
format Online
Article
Text
id pubmed-5803866
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58038662018-02-14 Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1 Kuriki, Reiko Hata, Tsuyoshi Nakayama, Kinuyo Ito, Yuichi Misawa, Kazunari Ito, Seiji Tatematsu, Michiko Kaneda, Norio J Pharm Health Care Sci Research Article BACKGROUND: Most eye disorders are not fatal but may deteriorate the quality of life of a patient. The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). However, preventive methods or treatment methods for the eye disorder have not yet been established. This study aimed to determine changes in tear volume and subjective ocular symptoms during the treatment period in patients receiving S-1 monotherapy for early detection of adverse effects in the eye and establishment of its treatment methods. METHODS: This study included eleven patients receiving S-1 monotherapy as a postoperative adjuvant chemotherapy for gastric cancer. Six subjective ocular symptoms including watering eyes were evaluated and changes in tear volume measured by the Schirmer’s test in patients receiving S-1 during the treatment period. In the present study, the patients were divided into “no watering eyes” (patients not experienced watering eyes) group and “watering eyes” (patients experienced watering eyes even once) group. RESULTS: Six out of eleven patients developed watering eyes after receiving S-1 monotherapy. Among these, the earliest onset occurred on the 2nd week after oral administration. Watering eyes and eye discharge were highly related in patients having a trouble in daily life due to the decreased QOL. Changes in tear volume in the “watering eyes” group significantly increased compared to the “no watering eyes” group during the treatment period, especially when the patients had no subjective symptom of the increased tear volume. CONCLUSIONS: It is essential to prevent eye disorders including watering eyes as an adverse effect of S-1 administration. The present study recommends that the tear volume should be periodically measured using Schirmer’s test, and the patient should be interviewed regarding the subjective ocular symptoms for the early detection of watering eyes caused by S-1 administration. If the tear volume can not be measured periodically, medical staffs should pay attention to the patient with eye discharge. BioMed Central 2018-02-07 /pmc/articles/PMC5803866/ /pubmed/29445512 http://dx.doi.org/10.1186/s40780-018-0100-8 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kuriki, Reiko
Hata, Tsuyoshi
Nakayama, Kinuyo
Ito, Yuichi
Misawa, Kazunari
Ito, Seiji
Tatematsu, Michiko
Kaneda, Norio
Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
title Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
title_full Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
title_fullStr Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
title_full_unstemmed Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
title_short Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
title_sort changes in tear volume and ocular symptoms of patients receiving oral anticancer drug s-1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803866/
https://www.ncbi.nlm.nih.gov/pubmed/29445512
http://dx.doi.org/10.1186/s40780-018-0100-8
work_keys_str_mv AT kurikireiko changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1
AT hatatsuyoshi changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1
AT nakayamakinuyo changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1
AT itoyuichi changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1
AT misawakazunari changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1
AT itoseiji changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1
AT tatematsumichiko changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1
AT kanedanorio changesintearvolumeandocularsymptomsofpatientsreceivingoralanticancerdrugs1